CEO UPDATE: NPHC We need to file our 10Q next week. After that, we can announce our ‘go-forward’ plans for the company. This includes: the ongoing infomercial campaign for Pet Pain-Away; the marketing of Nyloxin; the retail rollout for Nyloxin; the ongoing efforts to get our products into the VA and government buyers; our efforts in International registrations for our products; and our efforts in moving RPI-78M into clinical trials for Pediatric Multiple Sclerosis under our Orphan Designation. We are working with finance partners and potential joint venture partners to bring in from $2M to $20M in furtherance of the business plan. We expect to make announcements later this month to update our shareholders.
Market Data 
Markets 
AI
